ResMed Financial Indicators Patterns

RMD -- USA Stock  

USD 102.69  0.56  0.54%

Use fundamental data analysis to confirm all available drivers of ResMed to find out if markets are presently mispricing the firm. We found thirty-eight available financial ratios for ResMed which can be compared to its competitors. To make sure the equity is not overpriced, please check all ResMed fundamentals including its Revenue, Current Ratio, Market Capitalization, as well as the relationship between Cash and Equivalents and Earnings Per Share . Given that ResMed has Price to Earning of 52.60 times, we recommend you check out ResMed recent market performance to make sure the company can sustain itself down the road.Use ResMed to protect against small markets fluctuations. The stock experiences moderate downward daily trend and can be a good diversifier. Check odds of ResMed to be traded at $100.64 in 30 days

Enterprise Value

ResMed Company Summary

ResMed competes with DENTSPLY SIRONA, Stryker, Teleflex Incorporated, and Varian Medical. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and is traded on New York Stock Exchange. It employs 5940 people.

ResMed Shares Owned by Institutions vs Price to Earnings To Growth

ResMed is rated below average in shares owned by institutions category among related companies. It is rated below average in price to earnings to growth category among related companies producing about  0.06  of Price to Earnings To Growth per Shares Owned by Institutions. The ratio of Shares Owned by Institutions to Price to Earnings To Growth for ResMed is roughly  15.95 

ResMed Systematic Risk

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on ResMed correlated with the market. If Beta is less than 0 ResMed generally moves in the opposite direction as compared to the market. If ResMed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ResMed is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ResMed is generally in the same direction as the market. If Beta > 1 ResMed moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Distress Rating

ResMed Financial Distress Probability

Chance of Financial Distress
ResMed has less than 2 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

ResMed Thematic Clasifications

Active Themes With ResMed

Obamacare Repeal Idea
Obamacare RepealView

Compare ResMed

Compare ResMed To Peers

ResMed Opportunity Range

October 16, 2018 Opportunity Range

Additionally take a look at Your Equity Center. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.